IMbrave150: Atezolizumab plus Bevacizumab in HCC: Efficacy Data and Clinical Practice Implications : Episode 8
Advanced HCC: Key Takeaways
Key opinion leaders summarize essential takeaways and highlight unmet needs in the hepatocellular carcinoma treatment landscape.
Video Player is loading.
EP: 1.IMbrave 150: Overview
EP: 2.IMbrave 150: Patient Characteristics
EP: 3.IMbrave 150: Updated Outcomes
EP: 4.Using Atezolizumab + Bevacizumab in Practice
EP: 5.Vp4 and Baseline Varices Data in IMbrave 150: Clinical Implications
EP: 6.AE Management with Atezolizumab + Bevacizumab
EP: 7.CheckMate 9DW: Overview
Now Viewing
EP: 8.Advanced HCC: Key Takeaways
Video content above is prompted by the following:
- What are some key takeaways from this analysis?
- What are some clinical pearls you wish to offer your community colleagues who are considering treating their patients with atezo + bev? (EGD consideration, etc)
- What are some unmet needs in the treatment of advanced HCC?
Recent Videos
Patient Case Presentation: Patient on ESA for First-Line Therapy and Not Receiving a Marked Response—What Do You Do Next, and Why?
Key Takeaways and Future Directions in Later Relapsed/Refractory MM
Patient Case Presentation: Patient Is RBC Transfusion Eligible—Would You Proceed to Transfusion or Initiate Long-Term Anemia Treatment Strategies?
Key Takeaways/Final Comments
PERSEUS Trial: Adverse Events
PERSEUS Trial: Progression-Free Survival
CARTITUDE-1 Efficacy Findings
Patient Education and IRR Prophylaxis in Practice With Amivantamab/Lazertinib
Optimal Dosing of Talquetamab
Future of R/R MM: Emerging Bispecifics and Trispecifics
Related Content
